Samsung   Report issue

For profit Phase 1 Phase 3 Phase 4
Founded: Seoul Korea, Republic of (1938)
Status: No NME R&D (1938)

Organization Overview

First Clinical Trial
2013
NCT02482649
First Marketed Drug
2017
infliximab (remicade)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Samsung Bioepis Co., Ltd. | SAMSUNG BIOEPIS CO LTD | Samsung Electronics | Samsung Pharmaceutical Co., Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 4)

Arthritis, Rheumatoid (Phase 4)

Breast Neoplasms (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Hemoglobinuria (Phase 3)

Hemoglobinuria, Paroxysmal (Phase 3)

Lung Neoplasms (Phase 3)

Macular Degeneration (Phase 3)

Osteoporosis (Phase 3)

Osteoporosis, Postmenopausal (Phase 3)

Pancreatic Neoplasms (Phase 3)

Wet Macular Degeneration (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 31
  • # of Trial APIs: 22